Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells

Medical Science Monitor

Volumn 8, Issue 12, 2002, Pages

  Camirand, Anne ^a,b   Lu, Yuhong ^a   Pollak, Michael ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Co targeting; HER2 ErbB2; Herceptin; IGF 1R; Synergy; Trastuzumab

Indexed keywords

HEAT SHOCK PROTEIN 70; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FEMALE; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; ONCOGENE NEU; PROMOTER REGION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL DIVISION; DOWN-REGULATION; FEMALE; GENE EXPRESSION; HUMANS; PLASMIDS; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; TEMPERATURE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036963448     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Sawyers CL: Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Genet Dev, 2002; 1: 111-115
2. Hung MC, Lau YK: Basic science of HER2/neu: a review. Seminars in Oncol, 1999; 26(4) suppl. 12: 51-59
3. Kraus MH, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor related proto-oncogene erbB2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J, 1987; 6: 605-610
4. Harari D, Yarden Y: Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene, 2000; 19: 6102-6114
5. Baselga J, Albanell J: Mechanism of action of anti-HER2 monoclonal antibodies. Annals of Oncol, 2001; 12 (suppl. 1): S35-S41
6. Le XF, McWatters A, Wiener J et al: Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res, 2000; 6: 260-270
7. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Med, 2000; 6: 443-446
8. Albanell J, Baselga J: Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-1 receptor, a new suspect. J Natl Cancer Inst, 2001; 93: 1830-1832
9. Ye D, Mendelsohn J, Fan Z: Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27kip1 and costimulate proliferation ofMDA Pca 2a and MDA Pca 2b prostate cancer cells. Clin Cancer Res, 1999; 5: 2171-2177
10. Lu YH, Zi X, Zhao Y et al: Insulin-like growth factor 1 receptor signaling and resistance to Trastuzumab (Herceptin). J Nat Cancer Inst, 2001; 93: 1852-1857
11. Moasser MM, Basso A, Averbuch SD, Rosen N: The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res, 2001; 61: 7184-7188
12. Moulder SL, Yakes FM, Muthuswamy SK et al: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res, 2001; 61: 8887-8895
13. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor-1 mediates resistance to anti-epidermal growth factor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res, 2002; 61: 200-207
14. Totpal K, Lewis Phillips GD, Balter I, Sliwkowski MX: Augmentation of rhuMAb2C4-induced growth inhibition by Tarceva the EGFR tyrosine kinase inhibitor on human breast cancer cell lines. Proc Am Assoc Cancer Res, 2002; 43: 3889
15. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Rev, 2000; 21: 215-244
16. Reiss K, D'Ambrosio C, Tu X et al: Inhibition of tumour growth by a dominant-negative mutant of the insulin-like growth factor 1 receptor with a bystander effect. Clin Cancer Res, 1998; 4: 2647-2655
17. Arteaga CL, Kitten LJ, Coronado EB et al: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest, 1989; 84: 1418-1423
18. Andrews DW, Resnicoff M, Flanders AE et al: Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type 1 receptor in malignant astrocytomas. J Clin Oncol, 2001; 19: 2189-2200
19. Baserga R, Morrione A: Differentiation and malignant transformation: two roads diverged in a wood. J Cellular Biochem, 1999; Suppl. 32/33: 68-75
20. Romano G, Reiss K, Tu X et al: Efficient in vitro and in vivo gene regulation of a retrovirally delivered pro-apoptotic factor under the control of the Drosophila HSP70 promoter. Gene Ther, 2001; 8: 600-607
21. Gatzka M, Prisco M, Baserga R: Stabilization of the ras oncoprotein by the insulin-like growth factor 1 receptor during anchorage-independent growth. Cancer Res, 2000; 60: 4222-4230
22. Berenbaum M: Criteria for analyzing interactions between biologically active agents. Adv Cancer Res, 1981; 35: 269-335
23. Gessner PK: Isobolographic analysis of interactions: an update on applications and utility. Toxicology, 1995; 105: 161-179
24. Valentinis B, Morrione A, Peruzzi F et al: Anti-apoptotic signaling of the IGF-1 receptor in fibroblasts following loss of matrix adhesion. Oncogene, 1999; 18: 1827-1836
25. Baserga R: The price of independence. Exp Cell Res, 1997; 236: 1-3
26. D'Ambrosio C, Ferber A, Resnicoff M, Baserga RA: A soluble insulin-like growth factor-1 receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res, 1996; 56: 4013-4020
27. Reiss K, Tu X, Romano G et al: Intracellular association of a mutant insulin-like growth factor receptor with endogenous receptors. Clin Cancer Res, 2001; 7: 2134-2144
28. Luna MC, Ferrario A, Wong S et al: Photodynamic therapy-mediated oxidative stress as a molecular switch for the temporal expression of genes ligated to the human heat shock promoter. Cancer Res, 2000; 60: 1637-1644
29. Borrelli MJ, Schoenherr DM, Wong A et al: Heat-activated transgene expression from adenovirus vectors infected into human prostate cancer cells. Cancer Res, 2001; 61: 1113-1121
30. Pegram M, Hsu S, Lewis G et al: Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene, 1999; 18: 2241-22510
31. Dupont J, Karas M, LeRoith D: The potentiation of estrogen on insulin-like growth factor-1 action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem, 2000; 275: 35893-35901
32. Ram TG, Dilts CA, Dziubinski ML et al: Insulin-like growth factor and epidermal growth factor independence in human carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Molec Carcinogenesis, 1996; 15: 227-238